Should a company be permitted to patent a mutated human gene that can be targeted for therapy or an endogenous protein that they would like to produce as a therapeutic
Should a company be permitted to patent a mutated human gene that can be targeted for therapy or an endogenous protein that they would like to produce as a therapeutic? 1. The landscape of clinical trials has changed drastically over the last decade. The protocols are becoming more complex, leading to increased workload, burden on patients, and longer treatment times. Additionally, there has been an increase in the number of Phase 3 projects terminated, resulting in increasing costs of drug development – which is […]